Exclusive Summary

• - Patents long expired; 0.05% (5 mg/10 mL) OTC status in many countries enables simplified registration and fast launch.
• - Massive global need: allergic rhinitis ~400–600 million patients and colds cause billions of congestion episodes annually, driving steady retail and hospital demand.
• - Rapid onset with up to ~12-hour relief; guidelines endorse short-term (≤3–5 days) adjunctive use for severe nasal obstruction.
• - Despite mature competition, differentiation via metered pumps, preservative-free/low-irritation formulas, and private-label partnerships can win shelf space.
• - Clear price advantage vs leading brands (typically 30–70% lower retail), enabling strong value positioning and higher sell-through.